Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 5/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12558479 | 0.98 | PADI4 (0.55) | PADI4CYP19A1TBXAS1MEN1KMT2A | |
| SCHEMBL12558504 | 0.86 | CNR2 (0.58) | HTR6HTR2ACNR2CDC25A | |
| SCHEMBL17943470 | 0.84 | CDC25A (0.57) | PADI4HTR6POLBHTR2ACNR2 | |
| SCHEMBL4535061 | 0.84 | HTR2A (0.65) | PADI4CYP19A1TBXAS1MEN1KMT2A | |
| SCHEMBL11359456 | 0.84 | PADI4 (0.56) | PADI4CYP19A1TBXAS1MEN1KMT2A | |
| SCHEMBL25028278 | 0.83 | PADI4 (0.52) | PADI4CYP19A1TBXAS1MEN1KMT2A | |
| SCHEMBL18683661 | 0.83 | GPR84 (0.60) | PADI4CYP19A1TBXAS1MEN1KMT2A | |
| SCHEMBL10654844 | 0.83 | CYP19A1 (0.56) | PADI4CYP19A1TBXAS1MEN1KMT2A | |
| SCHEMBL5469549 | 0.81 | CYP19A1 (0.59) | PADI4CYP19A1TBXAS1MEN1KMT2A | |
| SCHEMBL9208449 | 0.81 | POLB (0.68) | PADI4CYP19A1TBXAS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | PADI4 474/4885CYP19A1 19/4885TBXAS1 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.